|
|
|
School
|
Status
|
Round
|
Year
|
GMAT
GRE
|
GPA
|
YOE
Years of Experiance
|
Post-MBA industry
|
Location
|
Date
|
|---|---|---|---|---|---|---|---|---|---|
|
Sloan MIT
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 735 GMAT Focus | 3.6 | 7 | Consulting | United States |
19 Feb 2025 08:34 AM
|
|
Wharton
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 735 GMAT Focus | 3.6 | 7 | Consulting | United States |
19 Feb 2025 08:34 AM
|
|
Wharton
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 655 GMAT Focus 705 GMAT Focus |
3.4 | 4 | Finance: Private Equity | United States |
19 Feb 2025 08:29 AM
|
|
Wharton
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 615 GMAT Focus 675 GMAT Focus |
3.2 | 7 | Consulting | United States |
19 Feb 2025 08:18 AM
|
|
Wharton
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 695 GMAT Focus | 6.1 | 5 | Consumer Packaged Goods | India |
19 Feb 2025 08:18 AM
|
|
Fuqua
Fuqua Weekend Executive Program |
Admitted, ($)
|
Round 2 | 2025 | 625 GMAT Focus | 3.8 | 17 | Healthcare/Pharmaceuticals | United States |
19 Feb 2025 08:17 AM
|
|
Wharton
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 695 GMAT Focus | 3.7 | 6 | Real Estate | Romania |
19 Feb 2025 08:17 AM
|
|
Wharton
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 695 GMAT Focus | 3.2 | 0 | Healthcare/Pharmaceuticals | India |
19 Feb 2025 08:16 AM
|
|
Wharton
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 735 GMAT Focus | 3.5 | 1 | Other | United States |
19 Feb 2025 08:15 AM
|
|
Fuqua
Full Time MBA |
Denied without Interview
|
Round 1 | 2025 | 685 GMAT Focus 720 GMAT Classic |
7.2 | 4 | Technology | India |
19 Feb 2025 03:17 AM
|
|
ESSEC
ESSEC Master in Management |
Admitted
|
R2 | 2025 | 645 GMAT Focus | 7.3 | 1 | Consulting | India |
19 Feb 2025 02:48 AM
|
|
Anderson
Full Time MBA |
Invited to Interview
|
Round 2 | 2025 | 750 GMAT Classic | 4 | Technology | India |
18 Feb 2025 10:35 PM
|
|
|
HEC Paris
September Intake |
Admitted, ($)
|
Round 1 | 2025 | 331 GRE | 3.5 | 8 | Pharmaceuticals and Biotech | United States |
18 Feb 2025 12:24 PM
|
|
Sloan MIT
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 332 GRE | 3.5 | 3 | Consulting | United States |
18 Feb 2025 12:02 PM
|
|
Sloan MIT
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 655 GMAT Focus 705 GMAT Focus |
3.4 | 4 | Finance: Private Equity | United States |
18 Feb 2025 10:50 AM
|
|
Sloan MIT
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 735 GMAT Focus | 3.5 | 1 | Other | United States |
18 Feb 2025 10:39 AM
|
|
Sloan MIT
Full Time MBA |
Denied without Interview
|
Round 1 | 2025 | 685 GMAT Focus | 5 | Finance | China |
18 Feb 2025 10:19 AM
|
|
|
Sloan MIT
Full Time MBA |
Denied without Interview
|
Round 1 | 2025 | 695 GMAT Focus | 3.7 | 5 | Energy | United States |
18 Feb 2025 10:15 AM
|
|
Sloan MIT
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 695 GMAT Focus | 3.2 | 0 | Healthcare/Pharmaceuticals | India |
18 Feb 2025 10:11 AM
|
|
Sloan MIT
Full Time MBA |
Denied without Interview
|
Round 2 | 2025 | 320 GRE | 6 | Healthcare/Pharmaceuticals | United Kingdom |
18 Feb 2025 10:10 AM
|